Fibrosis and Anti-TNF

Fibrosis and Anti-TNF


The fibrosis and anti-TNF program is based at the Kennedy Institute, at the University of Oxford in the UK.

The team in this project is led by Professor Jagdeep Nanchahal, a surgeon-scientist who has been running the phase 2 trials, and Professor Sir Marc Feldmann, a renowned immunologist and one of the pioneers of anti-TNF therapy.

Feldmann was instrumental in developing infliximab (Remicade) as a treatment for rheumatoid arthritis, now one of the best-selling drugs in the world and the main driver behind Johnson & Johnson’s $4.9 billion acquisition of Centocor in 1998.

Professor Sir Marc Feldmann in the Kennedy Institute at the University of Oxford

This program is developing therapies for:

Early stage Dupuytren’s disease (DD)

Phase 2b/3 Clinical Trials - Results expected Q1/2 2021

Approval only from MHRA/CCMO and relevant accredited ethics committees.
Frozen shoulder

Preclinical trials expected Q4 2020

Post operative cognitive decline (POCD)

Preclinical trials expected Q4 2020

Liver fibrosis (NASH)

Initial lab studies with Celgene-BMS on human tissue; preclinical studies to begin Q2 2020

Primary Indication – Dupuytren’s Disease (DD)

180 Life Sciences is trialling repurposing of anti-TNF drugs – commonly used in arthritic conditions – to treat early-stage DD.

Phase 2a Trial

The phase 2a trial was completed in 2018, with results that have allowed progress to a phase 2b/3 trial. Adalimumab was shown to be effective in treating early-stage DD. The dose-ranging trial was conducted on 28 patients.

Nanchahal, Jagdeep, et al. (2018)
Anti-tumour necrosis factor therapy for Dupuytren's disease: a randomised dose response proof of concept phase 2a clinical trial.

EBioMedicine 33: 282-288.
Phase 2b/3 Trial

The next phase is projected to receive results in 2021. 181 patients in Edinburgh, Oxford, and Amsterdam will receive an optimized dose of adalimumab for 18 months. This trial is fully enrolled and paid for.

View the trial details